232 related articles for article (PubMed ID: 35842231)
1. Content validity of the Recap of atopic eczema (RECAP) instrument in Dutch, English and German to measure eczema control in young people with atopic eczema: a cognitive interview study.
Gabes M; Ragamin A; Baker A; Kann G; Donhauser T; Gabes D; Howells L; Thomas KS; Oosterhaven JAF; Pasmans SGMA; Schuttelaar ML; Apfelbacher C
Br J Dermatol; 2022 Dec; 187(6):919-926. PubMed ID: 35842231
[TBL] [Abstract][Full Text] [Related]
2. The German RECAP questionnaire: linguistic validation and cognitive debriefing in German adults with self-reported atopic eczema and parents of affected children.
Gabes M; Tischer C; Herrmann A; Howells L; Apfelbacher C
J Patient Rep Outcomes; 2021 Jan; 5(1):13. PubMed ID: 33475902
[TBL] [Abstract][Full Text] [Related]
3. Development and initial testing of a new instrument to measure the experience of eczema control in adults and children: Recap of atopic eczema (RECAP).
Howells LM; Chalmers JR; Gran S; Ahmed A; Apfelbacher C; Burton T; Howie L; Lawton S; Ridd MJ; Rogers NK; Sears AV; Spuls P; von Kobyletzki L; Thomas KS
Br J Dermatol; 2020 Sep; 183(3):524-536. PubMed ID: 31794074
[TBL] [Abstract][Full Text] [Related]
4. The construct validity, responsiveness, reliability and interpretability of the Recap of atopic eczema questionnaire (RECAP) in children.
Ragamin A; Zhang J; Pasmans SGMA; Schappin R; Romeijn GLE; van Reusel MA; Oosterhaven JAF; Schuttelaar MLA
Br J Dermatol; 2024 May; 190(6):867-875. PubMed ID: 38262143
[TBL] [Abstract][Full Text] [Related]
5. Spanish Version of the RECAP Questionnaire to Assess Control of Atopic Eczema: Translation, Cultural Adaptation, Validation, and Correlations with Other Patient-Reported Outcome Measures.
Onteniente-Gomis MM; Ortiz-Romero PL; Tous Romero F; Salamanca Castro AB; Ortiz de Frutos FJ
Actas Dermosifiliogr; 2023 Jun; 114(6):488-493. PubMed ID: 36935038
[TBL] [Abstract][Full Text] [Related]
6. [JAPANESE TRANSLATION AND LINGUISTIC VALIDATION OF THE RECAP OF ATOPIC ECZEMA (RECAP)].
Itonaga T; Yanagida N; Nishino M; Sato S; Ohmatsu H; Otake N; Makita E; Fukuie T; Miura T; Chiyotanda M; Suzuki M; Manabe T; Koike Y; Futamura M; Nagao M; Ogata M; Takayama R; Sugiyama A; Kataoka Y; Ishiuji Y; Masuda K; Tanaka A; Nakahara T; Murota H; Saeki H; Katoh N; Ebisawa M
Arerugi; 2023; 72(10):1240-1247. PubMed ID: 38092400
[TBL] [Abstract][Full Text] [Related]
7. Validation of the Recap of Atopic Eczema (RECAP) Measurement Instrument for Eczema Control in Adult Patients in an Asian Clinical Setting.
Yew YW; Phuan CZY; Zhao X; Howells L; Apfelbacher CJ
Acta Derm Venereol; 2024 May; 104():adv32323. PubMed ID: 38738773
[TBL] [Abstract][Full Text] [Related]
8. Validity, reliability, responsiveness and interpretability of the Recap of atopic eczema (RECAP) questionnaire.
Zhang J; Ragamin A; Romeijn GLE; Loman L; Oosterhaven JAF; Schuttelaar MLA
Br J Dermatol; 2023 Oct; 189(5):578-587. PubMed ID: 37463409
[TBL] [Abstract][Full Text] [Related]
9. A new instrument for assessing quality of life in atopic dermatitis: international development of the Quality of Life Index for Atopic Dermatitis (QoLIAD).
Whalley D; McKenna SP; Dewar AL; Erdman RA; Kohlmann T; Niero M; Cook SA; Crickx B; Herdman MJ; Frech F; Van Assche D
Br J Dermatol; 2004 Feb; 150(2):274-83. PubMed ID: 14996098
[TBL] [Abstract][Full Text] [Related]
10. Recommended core outcome instruments for health-related quality of life, long-term control and itch intensity in atopic eczema trials: results of the HOME VII consensus meeting.
Thomas KS; Apfelbacher CA; Chalmers JR; Simpson E; Spuls PI; Gerbens LAA; Williams HC; Schmitt J; Gabes M; Howells L; Stuart BL; Grinich E; Pawlitschek T; Burton T; Howie L; Gadkari A; Eckert L; Ebata T; Boers M; Saeki H; Nakahara T; Katoh N
Br J Dermatol; 2021 Jul; 185(1):139-146. PubMed ID: 33393074
[TBL] [Abstract][Full Text] [Related]
11. IDQoL, CDLQI and the 45-item CADIS received a sufficient content validity rating during the HOME VII meeting in Japan: a group discussion study.
Gabes M; Apfelbacher C;
J Eur Acad Dermatol Venereol; 2021 Feb; 35(2):458-463. PubMed ID: 32745352
[TBL] [Abstract][Full Text] [Related]
12. Cross-Cultural Validation of the RECAP of Atopic Eczema Question-naire in a Swedish Population.
Sigurdardottir G; Alsterholm M; Andersson CD; Bradley M; Sandström Falk M; Johansson EK; Lundqvist M; Sonesson A; Svensson Å; Theodosiou G; Vrang S; Von Kobyletzki LB
Acta Derm Venereol; 2024 Jun; 104():adv38889. PubMed ID: 38898676
[TBL] [Abstract][Full Text] [Related]
13. Measuring Atopic Eczema Control and Itch Intensity in Clinical Practice: A Consensus Statement From the Harmonising Outcome Measures for Eczema in Clinical Practice (HOME-CP) Initiative.
Leshem YA; Chalmers JR; Apfelbacher C; Katoh N; Gerbens LAA; Schmitt J; Spuls PI; Thomas KS; Howells L; Williams HC; Simpson EL;
JAMA Dermatol; 2022 Dec; 158(12):1429-1435. PubMed ID: 36223090
[TBL] [Abstract][Full Text] [Related]
14. Developing a proxy version of the Adult social care outcome toolkit (ASCOT).
Rand S; Caiels J; Collins G; Forder J
Health Qual Life Outcomes; 2017 May; 15(1):108. PubMed ID: 28526055
[TBL] [Abstract][Full Text] [Related]
15. Psychological and educational interventions for atopic eczema in children.
Ersser SJ; Cowdell F; Latter S; Gardiner E; Flohr C; Thompson AR; Jackson K; Farasat H; Ware F; Drury A
Cochrane Database Syst Rev; 2014 Jan; 2014(1):CD004054. PubMed ID: 24399641
[TBL] [Abstract][Full Text] [Related]
16. Measurement properties of patient-reported outcome measures for eczema control: a systematic review.
Stuart BL; Howells L; Pattinson RL; Chalmers JR; Grindlay D; Rogers NK; Grinich E; Pawlitschek T; Simpson EL; Thomas KS
J Eur Acad Dermatol Venereol; 2021 Oct; 35(10):1987-1993. PubMed ID: 33977561
[TBL] [Abstract][Full Text] [Related]
17. The HOME Core outcome set for clinical trials of atopic dermatitis.
Williams HC; Schmitt J; Thomas KS; Spuls PI; Simpson EL; Apfelbacher CJ; Chalmers JR; Furue M; Katoh N; Gerbens LAA; Leshem YA; Howells L; Singh JA; Boers M;
J Allergy Clin Immunol; 2022 Jun; 149(6):1899-1911. PubMed ID: 35351441
[TBL] [Abstract][Full Text] [Related]
18. Measurement properties of quality-of-life measurement instruments for infants, children and adolescents with eczema: a systematic review.
Heinl D; Prinsen CAC; Sach T; Drucker AM; Ofenloch R; Flohr C; Apfelbacher C
Br J Dermatol; 2017 Apr; 176(4):878-889. PubMed ID: 27543747
[TBL] [Abstract][Full Text] [Related]
19. Recommended core outcome instruments for health-related quality of life, long-term control and itch intensity in atopic eczema trials: results of the HOME VII consensus meeting.
Thomas KS; Apfelbacher CA; Chalmers JR; Simpson E; Spuls PI; Gerbens LAA; Williams HC; Schmitt J; Gabes M; Howells L; Stuart BL; Grinich E; Pawlitschek T; Burton T; Howie L; Gadkari A; Eckert L; Ebata T; Boers M; Saeki H; Nakahara T; Katoh N
Br J Dermatol; 2020 Nov; ():. PubMed ID: 33179283
[TBL] [Abstract][Full Text] [Related]
20. Measurement properties of quality of life measurement instruments for infants, children and adolescents with eczema: protocol for a systematic review.
Heinl D; Prinsen CA; Drucker AM; Ofenloch R; Humphreys R; Sach T; Flohr C; Apfelbacher C
Syst Rev; 2016 Feb; 5():25. PubMed ID: 26860189
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
